NCT04610320View on ClinicalTrials.gov

Daratumumab-SC for Highly Sensitized Patients Awaiting Heart Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

January 26, 2024

Study Completion Date

January 26, 2024

Conditions
AllosensitizationHeart Transplant Failure and Rejection
Interventions
DRUG

Daratumumab-SC

\>Daratumumab-SC 1800 mg subcutaneous weekly for 8 doses and then every other week for 2 doses.

Trial Locations (1)

94304

Stanford Health Care, Stanford

All Listed Sponsors
lead

Ronald Witteles

OTHER